Registry Platform Urologic Cancer

Inclusion Criteria:

Cohorts aRCC and aUBC (prospective)

• Female and male patients with aRCC or aUBC (locally advanced, inoperable ormetastatic)

• Patients at start of their first-line systemic treatment for aRCC or aUBC

• Written informed consent

• Patients participating in the PRO module: signing of in-formed consent form andcompletion of baseline questionnaire before start of initial systemic treatment

• Patients not participating in the PRO module: within twelve weeks after startof systemic first-line for aRCC or aUBC

• Age ≥ 18 years

Cohort High-risk MIUC (prospective and retrospective)

• Histologically proven muscle-invasive urothelial carcinoma (MIUC) of the lower orupper urinary tract (ICD-10 C65, C66, C67.x, C68.x). Mixed histologies are allowed (main compo-nent must be urothelial carcinoma, with minor variants accept-ed).

• Radical surgery (e.g., radical cystectomy, nephroureterecto-my) between October 1, 2021 and October 31, 2024.

• High-risk of recurrence, defined as follows: Post-operative, pathological tumorstatus

• ypT2-ypT4 and/or ypN+ and without clinically detectable metastases (M0) atcystectomy for patients with prior neo-adjuvant chemotherapy or

• pT3-pT4 and/or pN+ and without clinically detectable me-tastases (M0) atcystectomy for patients without prior neo-adjuvant chemotherapy.

• Age ≥ 18 years at the time of surgery.

• Written informed consent (only if patient is alive at time of data entry; notapplicable for inclusion of deceased patients' data)

Exclusion Criteria:

Cohorts aRCC and aUBC (prospective)

• Patients with prior systemic therapy for aRCC or aUBC

• No systemic treatment for aRCC or aUBC

Cohort High-risk MIUC (prospective and retrospective)

• Partial cystectomy or partial nephrectomy of the primary tumor as definitive therapy

• Metastatic disease (M1) at the time of surgery